R
Richard Pazdur
Researcher at Food and Drug Administration
Publications - 284
Citations - 14980
Richard Pazdur is an academic researcher from Food and Drug Administration. The author has contributed to research in topics: Cancer & Population. The author has an hindex of 47, co-authored 282 publications receiving 10681 citations. Previous affiliations of Richard Pazdur include Silver Spring Networks & University of Texas MD Anderson Cancer Center.
Papers
More filters
Journal ArticleDOI
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
Patricia Cortazar,Lijun Zhang,Michael Untch,Keyur Mehta,Joseph P. Costantino,Norman Wolmark,Hervé Bonnefoi,David Cameron,Luca Gianni,Pinuccia Valagussa,Sandra M. Swain,Tatiana M. Prowell,Sibylle Loibl,D. Lawrence Wickerham,Jan Bogaerts,José Baselga,Charles M. Perou,Gideon M. Blumenthal,Jens Uwe Blohmer,Eleftherios P. Mamounas,Jonas Bergh,Vladimir Semiglazov,Robert Justice,Holger Eidtmann,Soonmyung Paik,Martine Piccart,Rajeshwari Sridhara,Peter A. Fasching,Leen Slaets,Shenghui Tang,Bernd Gerber,Charles E. Geyer,Richard Pazdur,Nina Ditsch,Priya Rastogi,Wolfgang Eiermann,Gunter von Minckwitz +36 more
TL;DR: In this paper, the authors compared the three most commonly used definitions of pathological complete response (ypT0 ypN0, ypT0/is ypNs0, and ypTsN0/IsYPN0) for their association with EFS and overall survival in clinical trials of neoadjuvant treatment of breast cancer.
Journal ArticleDOI
FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors
TL;DR: The FDA approved pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H), or mismatch repair deficient (dMMR) solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options.
Journal ArticleDOI
FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell‐Induced Severe or Life‐Threatening Cytokine Release Syndrome
Robert Q. Le,Liang Li,Weishi Yuan,Stacy S. Shord,Lei Nie,Bahru A. Habtemariam,Donna Przepiorka,Ann T. Farrell,Richard Pazdur +8 more
TL;DR: This article summarizes key review findings that supported the approval of tocilizumab for treatment of severe or life‐threatening CAR T cell‐induced cytokine release syndrome.
Journal ArticleDOI
Tumor downstaging and sphincter preservation with preoperative chemoradiation in locally advanced rectal cancer: the M. D. Anderson Cancer Center experience
Nora A. Janjan,V. Khoo,James L. Abbruzzese,Richard Pazdur,Ronelle A. DuBrow,Karen R. Cleary,Pamela K. Allen,Patrick M. Lynch,Gary A. Glober,Robert A. Wolff,Tyvin A. Rich,John M. Skibber +11 more
TL;DR: Significant tumor downstaging results from preoperative chemoradiation allowing sphincter sparing surgery in over 40% of patients whose tumors were located < 6 cm from the anal verge and who otherwise would have required colostomy.
Journal ArticleDOI
FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy
Geoffrey Kim,Gwynn Ison,Amy E. McKee,Hui Zhang,Shenghui Tang,Thomas Gwise,Rajeshwari Sridhara,Eunice Y. Lee,Abraham Tzou,Reena Philip,Haw-Jyh Chiu,Tiffany K. Ricks,Todd R. Palmby,Anne Marie Russell,Gaetan Ladouceur,Elimika Pfuma,Hongshan Li,Liang Zhao,Qi Liu,Rajesh Venugopal,Amna Ibrahim,Richard Pazdur +21 more
TL;DR: The most common adverse reactions in patients treated with olaparib were anemia, nausea, fatigue, vomiting, diarrhea, dysgeusia, dyspepsia, headache, decreased appetite, nasopharyngitis/pharyngritis/upper respiratory infection, cough, arthralgia/musculoskeletal pain, myalgia, back pain, dermatitis/rash, and abdominal pain/discomfort.